Pramipexole Chloride API

Name	Pramipexole chloride
Chinese name	盐酸普拉克索
Cas Number	191217-81-9
Source	India
Qualifications	USDMF/-/-/-/-

Pramipexole hydrochloride was first approved by the U.S. FDA for the treatment of idiopathic Parkinson's disease in May 1997. It was the first drug approved by the FDA for the treatment of Parkinson's disease in the mid-1990s. It was listed in China under the trade name Sunfro, and its global sales exceeded US$1 billion that year. Pramipexole has a protective effect on damaged neurons, and the symptoms of shaking are also well controlled. The side effects are the least in the field of Parkinson's. It can avoid the nerve damage caused by long-term use of levodopa. Compared with levodopa, pramipexole can significantly reduce the occurrence of dopaminergic movement complications, while delaying and reducing the occurrence and degree of levodopa-related movement complications, and also alleviating the symptoms of depression associated with Parkinson’s disease. And it is superior to bromocriptine in improving the dysfunction of advanced Parkinson's disease, and is clinically recognized and accepted by doctors and Parkinson's disease patients. Among anti-Parkinson's disease drugs in national grade hospitals, Pramipexole ranked first in sales.

Hot Tags: pramipexole chloride api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Lapatinib Ditosylate API, Itraconazole Hydrochloride API, Edoxaban API, Aprepitant Aprepitant API, Troxagliptin Succinate API, Bemeprost API

• Previous: Baclofen API
• Next: Gefitinib API